Humoral immunogenicity and reactogenicity of the standard ChAdOx1 nCoV-19 vaccination in Taiwan

Jer-Hwa Chang; Jeng-Fong Chiou; Ching-Sheng Hung; Ming-Che Liu; Hui-Wen Chang; Shiao-Ya Hong; Cheng-Yi Wang; Yi-Ling Lin; Yi-Chen Hsieh; Chi-Li Chung; Ying-Shih Su; Shu-Tai Shen Hsiao; Doresses Liu; Jian-Jong Liang; Chun-Che Liao; Chih-Shin Chang; Kevin Shu-Leung Lai; Han-Chuan Chuang; Ko-Ling Chien; Wei-Ciao Wu; Yuan-Chii G Lee; Sey-En Lin; Yung-Kang Shen; Chiung-Fang Hsu; Jude Chu-Chun Wang; Shih-Hsin Hsiao

doi:10.3390/vaccines10020312

Humoral immunogenicity and reactogenicity of the standard ChAdOx1 nCoV-19 vaccination in Taiwan

Jer-Hwa Chang, Jeng-Fong Chiou, Ching-Sheng Hung, Ming-Che Liu, Hui-Wen Chang, Shiao-Ya Hong, Cheng-Yi Wang, Yi-Ling Lin, Yi-Chen Hsieh, Chi-Li Chung, Ying-Shih Su, Shu-Tai Shen Hsiao, Doresses Liu, Jian-Jong Liang, Chun-Che Liao, Chih-Shin Chang, Kevin Shu-Leung Lai, Han-Chuan Chuang, Ko-Ling Chien, Wei-Ciao WuYuan-Chii G Lee, Sey-En Lin, Yung-Kang Shen, Chiung-Fang Hsu, Jude Chu-Chun Wang, Shih-Hsin Hsiao

醫學生物技術暨檢驗學系

研究成果: Article › 同行評審

5 引文斯高帕斯（Scopus）

摘要

BACKGROUND: The ChAdOx1 nCoV-19 vaccine has been widely administered against SARS-CoV-2 infection; however, data regarding its immunogenicity, reactogenicity, and potential differences in responses among Asian populations remain scarce. METHODS: 270 participants without prior COVID-19 were enrolled to receive ChAdOx1 nCoV-19 vaccination with a prime-boost interval of 8-9 weeks. Their specific SARS-CoV-2 antibodies, neutralizing antibody titers (NT50), platelet counts, and D-dimer levels were analyzed before and after vaccination. RESULTS: The seroconversion rates of anti-RBD and anti-spike IgG at day 28 after a boost vaccination (BD28) were 100% and 95.19%, respectively. Anti-RBD and anti-spike IgG levels were highly correlated (r = 0.7891), which were 172.9 ± 170.4 and 179.3 ± 76.88 BAU/mL at BD28, respectively. The geometric mean concentrations (GMCs) of NT50 for all participants increased to 132.9 IU/mL (95% CI 120.0-147.1) at BD28 and were highly correlated with anti-RBD and anti-spike IgG levels (r = 0.8248 and 0.7474, respectively). Body weight index was statistically significantly associated with anti-RBD IgG levels (p = 0.035), while female recipients had higher anti-spike IgG levels (p = 0.038). The GMCs of NT50 declined with age (p = 0.0163) and were significantly different across age groups (159.7 IU/mL for 20-29 years, 99.4 IU/mL for ≥50 years, p = 0.0026). Injection-site pain, fever, and fatigue were the major reactogenicity, which were more pronounced after prime vaccination and in younger participants (vaccination in Taiwanese recipients.

原文	American English
頁數	14
期刊	Vaccines
卷	10
發行號	2
DOIs	https://doi.org/10.3390/vaccines10020312
出版狀態	Published - 17 2月 2022

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.3390/vaccines10020312

引用此

Chang, J.-H., Chiou, J.-F., Hung, C.-S., Liu, M.-C., Chang, H.-W., Hong, S.-Y., Wang, C.-Y., Lin, Y.-L., Hsieh, Y.-C., Chung, C.-L., Su, Y.-S., Hsiao, S.-T. S., Liu, D., Liang, J.-J., Liao, C.-C., Chang, C.-S., Lai, K. S.-L., Chuang, H.-C., Chien, K.-L., ... Hsiao, S.-H. (2022). Humoral immunogenicity and reactogenicity of the standard ChAdOx1 nCoV-19 vaccination in Taiwan. Vaccines, 10(2). https://doi.org/10.3390/vaccines10020312

@article{287d4629f1e8467a95035252ba78d441,

title = "Humoral immunogenicity and reactogenicity of the standard ChAdOx1 nCoV-19 vaccination in Taiwan",

abstract = "BACKGROUND: The ChAdOx1 nCoV-19 vaccine has been widely administered against SARS-CoV-2 infection; however, data regarding its immunogenicity, reactogenicity, and potential differences in responses among Asian populations remain scarce. METHODS: 270 participants without prior COVID-19 were enrolled to receive ChAdOx1 nCoV-19 vaccination with a prime-boost interval of 8-9 weeks. Their specific SARS-CoV-2 antibodies, neutralizing antibody titers (NT50), platelet counts, and D-dimer levels were analyzed before and after vaccination. RESULTS: The seroconversion rates of anti-RBD and anti-spike IgG at day 28 after a boost vaccination (BD28) were 100% and 95.19%, respectively. Anti-RBD and anti-spike IgG levels were highly correlated (r = 0.7891), which were 172.9 ± 170.4 and 179.3 ± 76.88 BAU/mL at BD28, respectively. The geometric mean concentrations (GMCs) of NT50 for all participants increased to 132.9 IU/mL (95% CI 120.0-147.1) at BD28 and were highly correlated with anti-RBD and anti-spike IgG levels (r = 0.8248 and 0.7474, respectively). Body weight index was statistically significantly associated with anti-RBD IgG levels (p = 0.035), while female recipients had higher anti-spike IgG levels (p = 0.038). The GMCs of NT50 declined with age (p = 0.0163) and were significantly different across age groups (159.7 IU/mL for 20-29 years, 99.4 IU/mL for ≥50 years, p = 0.0026). Injection-site pain, fever, and fatigue were the major reactogenicity, which were more pronounced after prime vaccination and in younger participants (vaccination in Taiwanese recipients.",

keywords = "Asian populations, ChAdOx1 nCoV-19, vaccine",

author = "Jer-Hwa Chang and Jeng-Fong Chiou and Ching-Sheng Hung and Ming-Che Liu and Hui-Wen Chang and Shiao-Ya Hong and Cheng-Yi Wang and Yi-Ling Lin and Yi-Chen Hsieh and Chi-Li Chung and Ying-Shih Su and Hsiao, {Shu-Tai Shen} and Doresses Liu and Jian-Jong Liang and Chun-Che Liao and Chih-Shin Chang and Lai, {Kevin Shu-Leung} and Han-Chuan Chuang and Ko-Ling Chien and Wei-Ciao Wu and Lee, {Yuan-Chii G} and Sey-En Lin and Yung-Kang Shen and Chiung-Fang Hsu and Wang, {Jude Chu-Chun} and Shih-Hsin Hsiao",

year = "2022",

month = feb,

day = "17",

doi = "10.3390/vaccines10020312",

language = "American English",

volume = "10",

journal = "Vaccines",

issn = "2076-393X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

Chang, J-H, Chiou, J-F, Hung, C-S, Liu, M-C, Chang, H-W, Hong, S-Y, Wang, C-Y, Lin, Y-L, Hsieh, Y-C, Chung, C-L, Su, Y-S, Hsiao, S-TS, Liu, D, Liang, J-J, Liao, C-C, Chang, C-S, Lai, KS-L, Chuang, H-C, Chien, K-L, Wu, W-C, Lee, Y-CG, Lin, S-E, Shen, Y-K, Hsu, C-F, Wang, JC-C & Hsiao, S-H 2022, 'Humoral immunogenicity and reactogenicity of the standard ChAdOx1 nCoV-19 vaccination in Taiwan', Vaccines, 卷 10, 編號 2. https://doi.org/10.3390/vaccines10020312

TY - JOUR

T1 - Humoral immunogenicity and reactogenicity of the standard ChAdOx1 nCoV-19 vaccination in Taiwan

AU - Chang, Jer-Hwa

AU - Chiou, Jeng-Fong

AU - Hung, Ching-Sheng

AU - Liu, Ming-Che

AU - Chang, Hui-Wen

AU - Hong, Shiao-Ya

AU - Wang, Cheng-Yi

AU - Lin, Yi-Ling

AU - Hsieh, Yi-Chen

AU - Chung, Chi-Li

AU - Su, Ying-Shih

AU - Hsiao, Shu-Tai Shen

AU - Liu, Doresses

AU - Liang, Jian-Jong

AU - Liao, Chun-Che

AU - Chang, Chih-Shin

AU - Lai, Kevin Shu-Leung

AU - Chuang, Han-Chuan

AU - Chien, Ko-Ling

AU - Wu, Wei-Ciao

AU - Lee, Yuan-Chii G

AU - Lin, Sey-En

AU - Shen, Yung-Kang

AU - Hsu, Chiung-Fang

AU - Wang, Jude Chu-Chun

AU - Hsiao, Shih-Hsin

PY - 2022/2/17

Y1 - 2022/2/17

N2 - BACKGROUND: The ChAdOx1 nCoV-19 vaccine has been widely administered against SARS-CoV-2 infection; however, data regarding its immunogenicity, reactogenicity, and potential differences in responses among Asian populations remain scarce. METHODS: 270 participants without prior COVID-19 were enrolled to receive ChAdOx1 nCoV-19 vaccination with a prime-boost interval of 8-9 weeks. Their specific SARS-CoV-2 antibodies, neutralizing antibody titers (NT50), platelet counts, and D-dimer levels were analyzed before and after vaccination. RESULTS: The seroconversion rates of anti-RBD and anti-spike IgG at day 28 after a boost vaccination (BD28) were 100% and 95.19%, respectively. Anti-RBD and anti-spike IgG levels were highly correlated (r = 0.7891), which were 172.9 ± 170.4 and 179.3 ± 76.88 BAU/mL at BD28, respectively. The geometric mean concentrations (GMCs) of NT50 for all participants increased to 132.9 IU/mL (95% CI 120.0-147.1) at BD28 and were highly correlated with anti-RBD and anti-spike IgG levels (r = 0.8248 and 0.7474, respectively). Body weight index was statistically significantly associated with anti-RBD IgG levels (p = 0.035), while female recipients had higher anti-spike IgG levels (p = 0.038). The GMCs of NT50 declined with age (p = 0.0163) and were significantly different across age groups (159.7 IU/mL for 20-29 years, 99.4 IU/mL for ≥50 years, p = 0.0026). Injection-site pain, fever, and fatigue were the major reactogenicity, which were more pronounced after prime vaccination and in younger participants (vaccination in Taiwanese recipients.

AB - BACKGROUND: The ChAdOx1 nCoV-19 vaccine has been widely administered against SARS-CoV-2 infection; however, data regarding its immunogenicity, reactogenicity, and potential differences in responses among Asian populations remain scarce. METHODS: 270 participants without prior COVID-19 were enrolled to receive ChAdOx1 nCoV-19 vaccination with a prime-boost interval of 8-9 weeks. Their specific SARS-CoV-2 antibodies, neutralizing antibody titers (NT50), platelet counts, and D-dimer levels were analyzed before and after vaccination. RESULTS: The seroconversion rates of anti-RBD and anti-spike IgG at day 28 after a boost vaccination (BD28) were 100% and 95.19%, respectively. Anti-RBD and anti-spike IgG levels were highly correlated (r = 0.7891), which were 172.9 ± 170.4 and 179.3 ± 76.88 BAU/mL at BD28, respectively. The geometric mean concentrations (GMCs) of NT50 for all participants increased to 132.9 IU/mL (95% CI 120.0-147.1) at BD28 and were highly correlated with anti-RBD and anti-spike IgG levels (r = 0.8248 and 0.7474, respectively). Body weight index was statistically significantly associated with anti-RBD IgG levels (p = 0.035), while female recipients had higher anti-spike IgG levels (p = 0.038). The GMCs of NT50 declined with age (p = 0.0163) and were significantly different across age groups (159.7 IU/mL for 20-29 years, 99.4 IU/mL for ≥50 years, p = 0.0026). Injection-site pain, fever, and fatigue were the major reactogenicity, which were more pronounced after prime vaccination and in younger participants (vaccination in Taiwanese recipients.

KW - Asian populations

KW - ChAdOx1 nCoV-19

KW - vaccine

U2 - 10.3390/vaccines10020312

DO - 10.3390/vaccines10020312

M3 - Article

SN - 2076-393X

VL - 10

JO - Vaccines

JF - Vaccines

IS - 2

ER -

Humoral immunogenicity and reactogenicity of the standard ChAdOx1 nCoV-19 vaccination in Taiwan

摘要

UN SDG

存取文件

指紋

引用此